Iovance Biotherapeutics experienced a 10% decline over the last week, amid market turbulence driven by escalating trade tensions and significant losses across major indexes. As broader market indices, including the Dow Jones and the Nasdaq, plummeted due to fears of a trade war, the company's shares mirrored the market's downward trajectory. Like many other biotech stocks, Iovance's decline could also be attributed to heightened investor anxiety about the economic outlook, with the Dow dropping 4% into correction territory. Despite a better-than-expected jobs report briefly boosting sentiment, widespread sell-offs persisted, impacting Iovance's performance.

Every company has risks, and we've spotted 2 possible red flags for Iovance Biotherapeutics you should know about.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Iovance Biotherapeutics experienced a substantial total return decline of 76.1% over the last year. This contrasts sharply with the broader US market, which showed a positive return of 8.4%. Likewise, Iovance underperformed its industry, as the US Biotechs sector posted a smaller decline of 8.7%. Factors contributing to Iovance's share performance include ongoing financial challenges, evidenced by sustained net losses. Although the company reported increased revenue, reaching US$164.07 million for the full year 2024, it remains unprofitable and had a cumulative net loss of US$372.18 million.

Additionally, executive changes marked a strategic period for Iovance, as Dan Kirby joined as Chief Commercial Officer in February 2025 to enhance market strategy. The company also reaffirmed optimistic revenue guidance for 2025 between US$450 million and US$475 million, aiming for high gross margins. Despite financial improvements, unprofitability and valuation concerns continue to weigh on investor sentiment.

Click here to discover the nuances of Iovance Biotherapeutics with our detailed analytical financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:IOVA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com